Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 12, 2010

Roche Taps Kinaxo for Phosphoproteomics Technology

  • Kinaxo Biotechnologies will apply its phosphoproteomics technology PhosphoScout® to support targeted treatment approaches currently under development at Roche Diagnostics. PhosphoScout enables the identification of regulated protein phosphorylation sites in response to therapeutic antibody or kinase-inhibitor treatment, according to Kinaxo.

    Using quantitative mass spectrometry, up to 15,000 phosphorylation sites can be monitored in a single experiment, the company claims. This facilitates analysis of the phosphoproteome in patient samples, animal models, and cell culture on a global scale.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »